A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2834-2842

  Kindler, H L ^a   Richards, D A ^b   Garbo, L E ^c   Garon, E B ^d   Stephenson, J J ^e   Rocha Lima, C M ^f   Safran, H ^g   Chan, D ^h   Kocs, D M ^b   Galimi, F ⁱ   Mcgreivy, J ⁱ   Bray, S L ^j   Hei, Y ⁱ   Feigal, E G ⁱ   Loh, E ⁱ   Fuchs, C S ^k  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b US Oncology Research   (United States)

^c US Oncology Research   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GREENVILLE HOSPITAL SYSTEM   (United States)

^f UNIVERSITY OF MIAMI   (United States)

^g Brown University Oncology Group   (United States)

^h Cancer Care Associates Medical Group Inc   (United States)

ⁱ AMGEN INC   (United States)

^j AMGEN LTD   (United Kingdom)

^k DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

AMG 479; Conatumumab; Ganitumab; Gemcitabine; Pancreatic cancer; Phase 2 trial

Indexed keywords

EID: 84862531853     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds142     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma v.2.2010. Fort Washington, PA: National Comprehensive Cancer Network, 2010.
4. Cunningham D, Chau I, Stocken DD et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-5518.
5. Poplin E, Feng Y, Berlin J et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27: 3778-3785.
6. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-2237.
7. Colucci G, Labianca R, Di Costanzo F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010; 28: 1645-1651.
8. Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-3622.
9. Philip PA, Benedetti J, Corless CL et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28: 3605-3610.
10. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
11. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
12. Bergmann U, Funatomi H, Yokoyama M et al. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995; 55: 2007-2011.
13. Hakam A, Fang Q, Karl R et al. Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig Dis Sci 2003; 48: 1972-1978.
14. Vaccaro V, Melisi D, Bria E et al. Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets 2011; 15: 1183-1196.
15. Beltran PJ, Mitchell P, Chung YA et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009; 8: 1095-1105.
16. Klinakis A, Szabolcs M, Chen G et al. Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci USA 2009; 106: 2359-2364.
17. Rosen LS, Puzanov I, Friberg G et al. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin Cancer Res 2012; in press.
18. Ozawa F, Friess H, Kleeff J et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 2001; 163: 71-81.
19. Smit VT, Boot AJ, Smits AM et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988; 16: 7773-7782.
20. Lemoine NR, Jain S, Hughes CM et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992; 102: 230-236.
21. Drosopoulos KG, Roberts ML, Cermak L et al. Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem 2005; 280: 22856-22867.
22. Kaplan-Lefko PJ, Graves JD, Zoog SJ et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther 2010; 9: 618-631.
23. Kindler HL, Garbo L, Stephenson J et al. A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC). J Clin Oncol 2009; 27: abstr 4501.
24. Herbst RS, Kurzrock R, Hong DS et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 2010; 16: 5883-5891.
25. Tolcher AW, Sarantopoulos J, Patnaik A et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009; 27: 5800-5807.
26. Stathopoulos GP, Syrigos K, Polyzos A et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol 2004; 15: 224-229.
27. Rocha Lima CM, Savarese D, Bruckner H et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20: 1182-1191.
28. Boeck S, Hoehler T, Seipelt G et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 2008; 19: 340-347.
29. Casper ES, Green MR, Kelsen DP et al. Phase II trial of gemcitabine (2,2?-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
30. Burris HA, III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
31. Javle MM, Varadhachary GR, Fogelman DR et al. Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer. J Clin Oncol 2011; 29: abstr 4026.
32. Philip PA, Goldman BH, Ramanathan MK et al. Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727). J Clin Oncol 2012; 30: abstr 198.
33. Von Hoff DD, Ramanathan RK, Borad MJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29: 4548-4554.
34. Doi T, Murakami H, Ohtsu A et al. Phase 1 study of conatumumab, a proapoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 68: 733-741.
35. Jassem J, Langer CJ, Karp DD et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28: abstr 7500.
36. Bayraktar S, Bayraktar UD, Rocha-Lima CM. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol 2010; 16: 673-682.
37. Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 2011; 103: 1093-1100.